<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03791827</url>
  </required_header>
  <id_info>
    <org_study_id>Pediatric lupus nephritis</org_study_id>
    <nct_id>NCT03791827</nct_id>
  </id_info>
  <brief_title>Multicenter Registry of Pediatric Lupus Nephritis in China</brief_title>
  <official_title>Multicenter Registry of Pediatric Lupus Nephritis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiqiang Dang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Children's Hospital Affiliated to Suzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Inner Mongolia Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Zhangjiajie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puyang Oilfield General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Maternal and Child Health Care Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital &amp; Yuying Children's Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yichang Central People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xian Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Yunnan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xinxiang Medical College</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Provincial Maternity and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaocheng People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Lanzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Hebei Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhengzhou Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi Women's &amp; Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Children's Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of the current treatment option&#xD;
      and outcome of pediatric lupus nephritis patients in China. Investigators will perform&#xD;
      prospective registration study among at least 35 pediatric nephrology medical centers in&#xD;
      China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission</measure>
    <time_frame>5 years</time_frame>
    <description>complete remission is defined as UPC&lt;0.2 mg/mg， or 24-hour urine protein&lt;150mg with normal kidney function and without hematuria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial remission</measure>
    <time_frame>5 years</time_frame>
    <description>Partial remission is defined as non-nephrotic range proteinura, decrease of urine protein ≥50%， and serum creatinine remains stable (±25% of baseline) or is improved but not normal yet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End stage renal disease (ESRD)</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>ESRD is defined as eGFR&lt;15ml/1.73m2, initiation of long-term dialysis or kidney</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Death of patients</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Lupus Nephritis</condition>
  <condition>Children</condition>
  <condition>Steroid</condition>
  <condition>Immunosuppressive Treatment</condition>
  <arm_group>
    <arm_group_label>Corticosteroid</arm_group_label>
    <description>Pediatric lupus nephritis treated with hydroxychloroquine and corticosteroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid and cyclophosphamide</arm_group_label>
    <description>Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid and mycophenolate mofetil</arm_group_label>
    <description>Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and mycophenolate mofetil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid and azathioprine</arm_group_label>
    <description>Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and azathioprine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid and tacrolimus</arm_group_label>
    <description>Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid and cyclosporine A</arm_group_label>
    <description>Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclosporine A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid, mycophenolate mofetil and tacrolimus</arm_group_label>
    <description>Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid, mycophenolate mofetil and tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retuximab</arm_group_label>
    <description>An option for refractory lupus nephritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.</description>
    <arm_group_label>Corticosteroid</arm_group_label>
    <arm_group_label>Corticosteroid and azathioprine</arm_group_label>
    <arm_group_label>Corticosteroid and cyclophosphamide</arm_group_label>
    <arm_group_label>Corticosteroid and cyclosporine A</arm_group_label>
    <arm_group_label>Corticosteroid and mycophenolate mofetil</arm_group_label>
    <arm_group_label>Corticosteroid and tacrolimus</arm_group_label>
    <arm_group_label>Corticosteroid, mycophenolate mofetil and tacrolimus</arm_group_label>
    <other_name>Steroid</other_name>
    <other_name>Prednisone</other_name>
    <other_name>Methylprednisone</other_name>
    <other_name>Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine is recommended as the basic therapy for lupus nephritis</description>
    <arm_group_label>Corticosteroid</arm_group_label>
    <arm_group_label>Corticosteroid and azathioprine</arm_group_label>
    <arm_group_label>Corticosteroid and cyclophosphamide</arm_group_label>
    <arm_group_label>Corticosteroid and cyclosporine A</arm_group_label>
    <arm_group_label>Corticosteroid and mycophenolate mofetil</arm_group_label>
    <arm_group_label>Corticosteroid and tacrolimus</arm_group_label>
    <arm_group_label>Corticosteroid, mycophenolate mofetil and tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.</description>
    <arm_group_label>Corticosteroid and cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d</description>
    <arm_group_label>Corticosteroid and mycophenolate mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>The recommended dose of azathioprine is 1.5 to 2mg/kg/d</description>
    <arm_group_label>Corticosteroid and azathioprine</arm_group_label>
    <arm_group_label>Corticosteroid, mycophenolate mofetil and tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h</description>
    <arm_group_label>Corticosteroid and tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h</description>
    <arm_group_label>Corticosteroid and cyclosporine A</arm_group_label>
    <arm_group_label>Corticosteroid, mycophenolate mofetil and tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses</description>
    <arm_group_label>Retuximab</arm_group_label>
    <other_name>anti-CD20 antibody</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 1200 pediatric lupus nephritis patients younger than 18 years old will be&#xD;
        enrolled from more than 35 pediatric nephrology medical centers nationwide&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosis of lupus nephritis:&#xD;
&#xD;
          -  Diagnosis of SLE according to the 1997 update of the 1982 American College of&#xD;
             Rheumatology revised criteria for classification of systemic lupus erythematosus&#xD;
&#xD;
          -  Either of the following: Positive urine protein detected 3 times within a week, or&#xD;
             24-hour urine protein&gt;150mg, or UPC&gt;0.2mg/mg, or urinary microalbumin above normal&#xD;
             range detected 3 times within a week, or microscopic examination erythrocyte&gt;5 RBC/HP,&#xD;
             or renal dysfunction including glomerular and/or tubular dyfunction, or abnormal renal&#xD;
             biopsy and the pathological changes are in accordance with lupus nephritis&#xD;
&#xD;
          -  The pathological diagnosis of kidney conforms to the International Society of&#xD;
             Nephrology and Society of Renal Pathology (ISN/RPS) standards in 2003&#xD;
&#xD;
        Exclusion Criteria (either of the following criteria):&#xD;
&#xD;
          -  Complicated with other systemic diseases, including basic diseases with clinical&#xD;
             significance&#xD;
&#xD;
          -  Patients with tumors&#xD;
&#xD;
          -  Patients with abnormal glucose metabolism&#xD;
&#xD;
          -  Immunodeficiency patients&#xD;
&#xD;
          -  Patients diagnosed as tuberculosis, or hepatitis B, or hepatitis C within three months&#xD;
             before treatment&#xD;
&#xD;
          -  Patients with other connective tissue diseases (such as Sjogren's syndrome, mixed&#xD;
             connective tissue disease, etc.)&#xD;
&#xD;
          -  Drug-induced lupus, congenital lupus and other secondary lupus&#xD;
&#xD;
          -  Renal histopathology with non-inflammatory necrotizing angiopathy or thrombotic&#xD;
             microangiopathy (TMA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiqiang Dang, M.D.</last_name>
    <phone>8613739052618</phone>
    <email>dangxiqiang@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tian Shen, M.D</last_name>
    <phone>8613548764640</phone>
    <email>shentian0215@csu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tian Shen, M.D.</last_name>
      <phone>+8613548764640</phone>
      <email>shentian0215@csu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 24, 2018</study_first_submitted>
  <study_first_submitted_qc>December 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Second Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Xiqiang Dang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Currently, IPD is not available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03791827
org study id: Pediatric lupus nephritis
nct id: NCT03791827
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
is us export: No
This study is designed to evaluate the efficacy and safety of the current treatment option
      and outcome of pediatric lupus nephritis patients in China. Investigators will perform
      prospective registration study among at least 35 pediatric nephrology medical centers in
      China.
observational model: Case-Only
time perspective: Prospective
measure: Complete remission
time frame: 5 years
description: complete remission is defined as UPC<0.2 mg/mg， or 24-hour urine protein<150mg with normal kidney function and without hematuria
measure: Partial remission
time frame: 5 years
description: Partial remission is defined as non-nephrotic range proteinura, decrease of urine protein ≥50%， and serum creatinine remains stable (±25% of baseline) or is improved but not normal yet
measure: End stage renal disease (ESRD)
time frame: 1 year, 2 years, 3 years, 4 years and 5 years
description: ESRD is defined as eGFR<15ml/1.73m2, initiation of long-term dialysis or kidney
measure: Mortality
time frame: 1 year, 2 years, 3 years, 4 years and 5 years
description: Death of patients
arm group label: Corticosteroid
description: Pediatric lupus nephritis treated with hydroxychloroquine and corticosteroid
arm group label: Corticosteroid and cyclophosphamide
description: Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclophosphamide
arm group label: Corticosteroid and mycophenolate mofetil
description: Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and mycophenolate mofetil
arm group label: Corticosteroid and azathioprine
description: Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and azathioprine
arm group label: Corticosteroid and tacrolimus
description: Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and tacrolimus
arm group label: Corticosteroid and cyclosporine A
description: Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclosporine A
arm group label: Corticosteroid, mycophenolate mofetil and tacrolimus
description: Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid, mycophenolate mofetil and tacrolimus
arm group label: Retuximab
description: An option for refractory lupus nephritis
intervention type: Drug
intervention name: Corticosteroid
description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
arm group label: Corticosteroid
arm group label: Corticosteroid and azathioprine
arm group label: Corticosteroid and cyclophosphamide
arm group label: Corticosteroid and cyclosporine A
arm group label: Corticosteroid and mycophenolate mofetil
arm group label: Corticosteroid and tacrolimus
arm group label: Corticosteroid, mycophenolate mofetil and tacrolimus
other name: Steroid
other name: Prednisone
other name: Methylprednisone
other name: Prednisolone
intervention type: Drug
intervention name: Hydroxychloroquine
description: Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
arm group label: Corticosteroid
arm group label: Corticosteroid and azathioprine
arm group label: Corticosteroid and cyclophosphamide
arm group label: Corticosteroid and cyclosporine A
arm group label: Corticosteroid and mycophenolate mofetil
arm group label: Corticosteroid and tacrolimus
arm group label: Corticosteroid, mycophenolate mofetil and tacrolimus
intervention type: Drug
intervention name: Cyclophosphamide
description: The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
arm group label: Corticosteroid and cyclophosphamide
intervention type: Drug
intervention name: Mycophenolate Mofetil
description: The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d
arm group label: Corticosteroid and mycophenolate mofetil
intervention type: Drug
intervention name: Azathioprine
description: The recommended dose of azathioprine is 1.5 to 2mg/kg/d
arm group label: Corticosteroid and azathioprine
arm group label: Corticosteroid, mycophenolate mofetil and tacrolimus
intervention type: Drug
intervention name: Tacrolimus
description: The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h
arm group label: Corticosteroid and tacrolimus
intervention type: Drug
intervention name: Cyclosporine A
description: The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h
arm group label: Corticosteroid and cyclosporine A
arm group label: Corticosteroid, mycophenolate mofetil and tacrolimus
intervention type: Drug
intervention name: Rituximab
description: The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
arm group label: Retuximab
other name: anti-CD20 antibody
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: N/A
maximum age: 18 Years
healthy volunteers: No
last name: Xiqiang Dang, M.D.
phone: 8613739052618
email: dangxiqiang@csu.edu.cn
last name: Tian Shen, M.D
phone: 8613548764640
email: shentian0215@csu.edu.cn
facility: 
status: Recruiting
contact: 
country: China
responsible party type: Sponsor-Investigator
investigator affiliation: Second Xiangya Hospital of Central South University
investigator full name: Xiqiang Dang
investigator title: Professor
mesh term: Nephritis
mesh term: Lupus Nephritis
mesh term: Cyclosporine
mesh term: Mycophenolic Acid
mesh term: Hydroxychloroquine
mesh term: Prednisone
mesh term: Prednisolone
mesh term: Cyclophosphamide
mesh term: Rituximab
mesh term: Azathioprine
mesh term: Tacrolimus
mesh term: Cyclosporins
sharing ipd: No
ipd description: Currently, IPD is not available to other researchers